Ribonucleic Acid Interference (RNAi) Technology Global Market Report 2025

The ribonucleic acid interference (RNAi) technology market size has grown rapidly in recent years. It will grow from $3.82 billion in 2024 to $4.43 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. Growth in the historic period can be attributed to increasing funding for genomics research, the rising prevalence of genetic and rare diseases, greater use of RNA interference in functional genomics studies, growing pharmaceutical interest in gene-silencing technologies, and expanding academic-industry collaborations.

The ribonucleic acid interference (RNAi) technology market size is expected to see rapid growth in the next few years. It will grow to $7.96 billion in 2029 at a compound annual growth rate (CAGR) of 15.7%. Growth in the forecast period can be attributed to a rise in clinical trial initiations and patient enrollment, increasing partnerships, mergers, and licensing agreements, growing healthcare spending on specialty and precision medicines, rising demand for personalized therapies, and the increasing burden of oncology and chronic liver diseases. Major trends expected in the forecast period include advancements in lipid nanoparticle delivery systems, development of N-acetylgalactosamine (GalNAc)-conjugate liver-targeting technologies, optimization of self-delivering siRNA platforms, artificial-intelligence-assisted design and off-target reduction for siRNA, and progress in exosome-mediated and cell-penetrating peptide-based delivery methods.

The increasing demand for targeted therapeutics is expected to drive the growth of the ribonucleic acid interference (RNAi) technology market in the coming years. Targeted therapies are designed to specifically target and inhibit molecular abnormalities in diseases such as cancer, improving treatment precision and minimizing harm to healthy cells. The rising emphasis on targeted therapies is primarily fueled by advancements in precision medicine, which enable personalized treatments based on an individual's genetic profile. RNAi technology plays a crucial role in this shift, enabling precise gene silencing to treat genetic and rare diseases. It supports the development of highly specific and effective treatments, spurring innovation in personalized medicine. For example, in December 2024, the American Society of Gene & Cell Therapy (ASGCT) reported that the U.S. Food and Drug Administration (FDA) approved 6 gene therapy products in 2023, up from 5 approvals in 2022. Therefore, the growing demand for targeted therapeutics is driving the expansion of the RNAi technology market.

Key players in the RNAi technology market are focusing on platform integration and securing strategic funding to streamline the development, delivery, and commercialization of RNAi therapeutics, ensuring a sustainable pipeline of programs across various disease areas. Strategic funding refers to securing investment from venture capital, industry partners, and other stakeholders to accelerate the research and development of RNAi-based medicines. For instance, in October 2024, City Therapeutics Inc., a US-based biopharmaceutical company, raised $135 million in Series A financing, led by ARCH Venture Partners with participation from other major life sciences investors. This funding will help develop RNAi-based medicines using the company’s proprietary lipid nanoparticle (LNP) delivery platform, which is designed to target tissues beyond the liver with high precision. This innovation aims to address a historical limitation in the RNAi field, enabling the development of therapies for a broader range of genetic disorders.

In July 2023, Novartis AG, a Swiss pharmaceutical company, acquired DTx Pharma Inc. for an undisclosed amount. This acquisition aims to strengthen Novartis' RNAi therapeutic capabilities and expand its neuromuscular disease portfolio through DTx Pharma’s FALCON delivery platform. DTx Pharma, a US-based preclinical-stage biotechnology company, specializes in RNA interference technology for the development of RNAi-based therapeutics.

Major companies operating in the ribonucleic acid interference (rnai) technology market are F. Hoffmann-La Roche AG, Merck KGaA, Novartis AG, Thermo Fisher Scientific Inc., Danaher Corporation, Revvity Inc., QIAGEN N.V., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., GenScript Biotech Corporation, Promega Corporation, Arrowhead Pharmaceuticals Inc., Silence Therapeutics plc, Creative Biolabs Inc., Bioneer Corporation, Genevant Sciences Ltd., Gradalis Inc., Altogen Labs LLC, Sirnaomics Inc., Altogen Biosystems Inc.

North America was the largest region in the ribonucleic acid interference (RNAi) technology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ribonucleic acid interference (RNAi) technology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ribonucleic acid interference (RNAi) technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The ribonucleic acid interference (RNAi) technology market research report is one of a series of new reports that provides ribonucleic acid interference (RNAi) technology market statistics, including ribonucleic acid interference (RNAi) technology industry global market size, regional shares, competitors with a ribonucleic acid interference (RNAi) technology market share, detailed ribonucleic acid interference (RNAi) technology market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid interference (RNAi) technology industry. This ribonucleic acid interference (RNAi) technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ribonucleic acid interference (RNAi) technology is a biological mechanism that regulates gene expression by using small RNA molecules to silence specific messenger RNA (mRNA) sequences. By controlling gene activity, it enables scientists to suppress or reduce the production of targeted proteins. This makes RNAi a powerful tool for inhibiting disease-related genes and supports genetic research, drug development, and therapeutic applications.

The main products in ribonucleic acid interference (RNAi) technology include micro ribonucleic acid (miRNA), small interfering ribonucleic acid (siRNA), and others. Micro ribonucleic acid (miRNA) consists of short, non-coding RNA molecules that bind to complementary mRNA sequences to block translation or promote degradation, thereby fine-tuning gene expression. Delivery methods include viral vectors, nanoparticles, chemical modifications, and physical techniques, with applications across therapeutics, drug discovery, agriculture, and diagnostics. RNAi technology is widely used by pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations (CROs) and contract manufacturing organizations (CMOs).

The ribonucleic acid interference (RNAi) technology consists of revenues earned by entities by providing services such as gene silencing services, custom ribonucleic acid (RNA) synthesis, oligonucleotide design, ribonucleic acid (RNA) sequencing, target validation, functional genomics screening, data analysis, drug discovery support, delivery system optimization, and molecular assay development. The market value includes the value of related goods sold by the service provider or included within the service offering. The RNA interference (RNAi) technology market also includes sales of microRNA mimics, transfection reagents, ribonucleic acid (RNA) delivery kits, plasmid vectors, assay kits, cell lines, reagents and buffers, and laboratory consumables. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.